10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.
暂无分享,去创建一个
Jette Borg | Andrew Evans | A. Evans | J. Crook | A. Toi | E. Saibishkumar | J. Borg | S. Fung | Juanita Crook | Clement Ma | Sharon Fung | Ants Toi | Clement Ma | E P Saibishkumar
[1] Yoshiya Yamada,et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.
[2] R. Stock,et al. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. , 2009, International journal of radiation oncology, biology, physics.
[3] R. Stock,et al. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.
[4] Ivan Yeung,et al. Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. , 2002, Brachytherapy.
[5] R. Stock,et al. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.
[6] G. Perry,et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. , 2000, International journal of radiation oncology, biology, physics.
[7] W. Butler,et al. Erectile function after permanent prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.
[8] G. Pond,et al. Long-term urinary sequelae following 125iodine prostate brachytherapy. , 2008, The Journal of urology.
[9] W. J. Morris,et al. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. , 2010, International journal of radiation oncology, biology, physics.
[10] W. J. Morris,et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. , 2009, Urology.
[11] J. Crook,et al. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Bristow,et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] M. Kattan,et al. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. , 2010, International journal of radiation oncology, biology, physics.
[14] R. Stock,et al. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function , 2006, BJU international.
[15] J. Ciezki,et al. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[16] G. Pond,et al. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. , 2006, Brachytherapy.
[17] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[18] Yoshiya Yamada,et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.
[19] R. Stock,et al. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. , 2010, The Journal of urology.
[20] Jose A Gonzalez,et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. , 2003, The Journal of urology.
[21] Alexandre Mamedov,et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Unger,et al. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. , 2008, International journal of radiation oncology, biology, physics.
[23] P. Carroll,et al. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. , 2007, The Journal of urology.
[24] L. Anderson,et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .
[25] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.
[26] C. Ménard,et al. Image guided dose escalated prostate radiotherapy: still room to improve , 2009, Radiation oncology.
[27] D. Beyer,et al. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.
[28] N. Mabjeesh,et al. Sexual function after permanent 125I-brachytherapy for prostate cancer , 2005, International Journal of Impotence Research.
[29] N. Mabjeesh,et al. Sexual function after permanent 125 I-brachytherapy for prostate cancer , 2004 .
[30] L. Potters,et al. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. , 2005, Brachytherapy.
[31] Blasko,et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International Journal of Radiation Oncology, Biology, Physics.
[32] Robert W Galbreath,et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. , 2007, International journal of radiation oncology, biology, physics.
[33] L. Potters,et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.
[34] M. Johnston,et al. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[35] M. Mclean,et al. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. , 2010, International journal of radiation oncology, biology, physics.
[36] G. Lockwood,et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.
[37] J. Cappelleri,et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction , 1999, International Journal of Impotence Research.
[38] Barry S Rosenstein,et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.